You just read:

NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

News provided by

Novartis

Jun 23, 2017, 12:07 ET